No Data
No Data
Leargate - In the 3Q, revenue and profit both increased by double digits, and an upward revision of full-year performance estimates was announced.
Realgate (5532) announced its earnings for the third quarter of the September 2024 fiscal year (October 2023-June 2024). Revenue increased by 24.1% to ¥6.471 billion compared to the same period last year, operating profit increased by 52.2% to ¥0.747 billion, ordinary profit increased by 44.4% to ¥0.639 billion, and net profit for the quarter increased by 66.1% to ¥0.443 billion. In the real estate industry, which is the company's main business, particularly in the rental market in Tokyo's central business district, there has been an improvement in the average vacancy rate for offices, etc.
Lear Gate - The financial estimates for the September 2024 term have been revised.
Realgate <5532> announced on the 30th that it will revise its performance forecast for the 2024 fiscal year ending September 30, 2023. The current business is progressing well due to high occupancy of existing properties throughout the year and higher than expected profits from the sale of investment properties. As a result, both revenue and operating profit are expected to exceed the previous forecast, and there is a certain prospect for opening new properties and investment acquisitions in the second half of the year. Therefore, the company has revised its performance forecast for the 2024 fiscal year ending in September to revenue of 7.85 billion yen (an increase of 1.9% from the previous forecast) and operating profit of 7.5.
Lear Gate, and other Lear Gate.
<3557> U&C digitizes shareholder benefits system. <4479> Macaukake's operating profit forecast for this fiscal year is -0.097 billion yen, revised downward from 0.016 billion yen. <5532> Lear raises its operating profit forecast for this fiscal year from 0.64 billion yen to 0.75 billion yen. <6182> Metalial enters into a joint research agreement with the National Cancer Center, a national research and development organization that handles research projects related to medical care for cancer and other malignant neoplasms.
Realgate: Financial presentation material for the third quarter of the September 2024 period.
Realgate: September 2024 Quarterly Earnings Report (Japan Standard) for the third quarter of the fiscal year (non-consolidated).
Realgate: Announcement of revised financial estimates.
No Data